IMMU 140

Drug Profile

IMMU 140

Alternative Names: IMMU-140

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Immunomedics
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action Antigen-presenting-cell-modulators; DNA topoisomerase I inhibitors; HLA-DR antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 06 Dec 2016 Pharmacodynamic results from a preclinical trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 15 Nov 2016 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 15 Nov 2016 Immunomedics has patent protection for IMMU-140 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top